Transforming drug manufacturing, starting with insulin
rBIO has developed a proprietary insulin manufacturing process and licensing platform that increases production output and improves the economics of essential peptide drugs.
The company is focused first on insulin, with a licensing-first model for qualified regional and strategic partners.
rBIO in a nutshell:
Insulin-first manufacturing platform
Proprietary process that increases output
Scale-up path toward 1,000L production
Licensing model for regional and global partners
Experienced leadership and investor-aligned commercialization plan
rBIO CEO Dr. Deen Bakthavatsalam explains the company’s insulin manufacturing process and licensing model, which aims to improve the economics of essential peptide drugs.
Business model
A licensing platform for insulin manufacturing
rBIO improves the production economics of insulin manufacturing.
The company has developed a proprietary manufacturing process that increases insulin output, supports lower-cost production, and creates a repeatable licensing model for qualified partners.
The problem we address:
Complex manufacturing drives high prices
Insulin remains a large, essential drug category, but manufacturing complexity continues to drive cost, margin pressure and supply vulnerability.
For manufacturers and regional partners, a more efficient insulin production process improves commercial economics while supporting broader access.
Investor relevance
Large essential-drug market
Persistent manufacturing inefficiency
Supply pressure as major manufacturers shift focus
Need for qualified regional production capacity
Potential for licensing-driven scale
rBIO’s solution
A proprietary process that increases output
rBIO’s process combines proprietary manufacturing know-how with an insulin-first development strategy.
The platform doubles the rate of insulin production compared with current industry production.
What rBIO has built
Proprietary insulin manufacturing process
Process IP and technical know-how
Bacteria-based production approach
Scale-up path from 20L pilot work to 1,000L production
Licensing model for qualified manufacturing partners
Our secret sauce
Current industry production
IP platform
Proprietary manufacturing process
Technical differentiation
What makes rBIO different
rBIO uses a bacterial production process that manufactures insulin more efficiently than conventional approaches.
The platform simplifies production economics and gives qualified partners a transferable process for regional insulin manufacturing.
Differentiation points
Bacteria-based production system
Proprietary process know-how
Designed for higher insulin output
Built for scale-up and licensing
Expandable to additional peptide drugs over time
| Differentiator | What it means | Investor relevance |
|---|---|---|
| Bacteria-based production system | rBIO uses a bacterial production process for insulin manufacturing rather than more complex conventional production methods. | Simplifies production economics and supports higher-output manufacturing. |
| Proprietary process know-how | rBIO’s value is centered on process design, manufacturing learning, scale-up methods and transfer-ready operating knowledge. | Creates a defensible operating advantage before patent language is finalized or publicly disclosed. |
| Increased output | rBIO’s process increases insulin production output compared with current industry production methods. | Higher output improves manufacturing economics, licensee economics and long-term platform value. |
| Scale-up path | rBIO has advanced from early process work toward a 1,000L scale-up milestone. | Creates a clear technical milestone on the path to process-ready licensing. |
| Licensing-ready model | rBIO’s process supports qualified manufacturing partners that can commercialize insulin in priority markets. | Enables a capital-efficient commercialization model without requiring rBIO to build and own every manufacturing asset. |
| Peptide platform expansion | Insulin is the first application, with expansion potential across additional peptide drugs. | Extends the platform story beyond the first insulin licensing opportunity. |
World-class team
rBIO brings together scientific, operational, financial and investor experience around a licensing-first commercialization strategy.
Dr. Deen Bakthavatsalam
CEO / Co-founder
Leads rBIO’s scientific and commercial strategy, bringing more than 27 years of experience across biotech development, clinical planning, IP strategy and commercialization.
Stuart Douglass
Executive Chairman
Supports governance, investor strategy and commercialization planning, with deep experience in manufacturing, facilities and company-building.
Shawn Swaney
CFO
Leads financial planning and investor readiness, with more than 29 years of finance leadership across high-growth technology, life-science and cleantech companies.
Dr. Judith Shizuru
Director
Brings Stanford physician-scientist, transplantation, stem-cell biology and biotech board experience to rBIO’s board.
Cameron Owen
Co-founder
Co-founded rBIO and helped establish the company’s early insulin platform, business plan and synthetic biology strategy.
Market
Large licensing opportunity, insulin-first entry point
rBIO enters the market through insulin licensing and expands across the broader peptide-drug licensing opportunity.
The company licenses insulin first, expands by geography and partner category, then extends the platform to additional peptide drugs.
A LOI is in place for the first licensing deal of insulin.
Global licensing market: $250 billion*
Competitive position
Where rBIO fits
rBIO sits at the intersection of insulin focus, licensing model, manufacturing know-how and future peptide expansion.
Unlike broad service providers or generalized peptide-platform startups, rBIO’s initial advantage is focused on insulin manufacturing economics and licensing-ready process transfer.
| Company Type | Insulin Focus | Licensing Model | Know-how | Multiple Peptides |
|---|---|---|---|---|
| rBIO | High | High | High | High |
| Contract Research Organization Ginkgo Bioworks | Low | High | Low | High |
| Other Startups Peptide platforms | Low | Emerging | Low | Emerging |
Customer and licensee targets
rBIO’s licensing model serves organizations that commercialize, manufacture, distribute or scale insulin and other peptide drugs in priority markets.
The initial target universe includes biosimilar players, traditional pharma companies and CDMOs with clear manufacturing, licensing or margin-pressure reasons to evaluate rBIO’s platform.
rBIO evaluates potential licensee categories based on their fit with the company’s insulin-first licensing model, including insulin focus, licensing receptivity, need for rBIO’s process know-how and margin pressure.
| Customer Type for rBIO | Insulin Fit | Licensing Fit | Need for rBIO Know-how | Margin-Pressure Fit |
|---|---|---|---|---|
| Biosimilar Players Civica Rx, Cost Plus | Strong fit | Strong fit | Lower fit | Strong fit |
| Traditional Pharma Lilly, Novo Nordisk, Sanofi | Strong fit | Lower fit | Moderate fit | Moderate fit |
| Contract Manufacturing / CDMO KPI Pharma, Cytovance, AGC Biologics | Lower fit | Strong fit | Strong fit | Strong fit |
Marketing strategy and moat
Beachhead strategy
rBIO prioritizes markets where insulin demand, partner access, manufacturing need and licensing potential create a practical commercialization path.
The company’s beachhead analysis evaluates target markets based on partner availability, market access, sales fit, research support, existing relationships and estimated LTV/CAC.
| Market | Product | Partner Availability | Market Access | Sales Fit | Research Support | Relationship Strength | LTV/CAC |
|---|---|---|---|---|---|---|---|
| Mexico | Regular insulin | Moderate fit | Moderate fit | Strong fit | Strong fit | Strong fit | 8.8 |
| U.S. | Regular insulin and detemir | Moderate fit | Moderate fit | Strong fit | Strong fit | Moderate fit | 8.3 |
| Middle East | Regular insulin | Lower fit | Moderate fit | Strong fit | Strong fit | Moderate fit | 8.0 |
| Spain | Regular insulin | Moderate fit | Moderate fit | Moderate fit | Strong fit | Moderate fit | 7.3 |
| LatAm / EU | Insulin glargine | Lower fit | Moderate fit | Moderate fit | Strong fit | Lower fit | 6.2 |
| LatAm / EU | Insulin lispro and aspart | Lower fit | Moderate fit | Moderate fit | Strong fit | Lower fit | 6.2 |
Partner categories include manufacturers, distributors and fill-finish owners.
Go-to-market strategy
Licensing drug manufacturers
rBIO commercializes through licensing rather than building and owning every manufacturing asset from the start.
The company works with qualified manufacturers, regional partners, CDMOs, distributors, and strategic pharma organizations.
Near-term go-to-market channels
Licensing conversations with drug manufacturers
Press release and investor communications
Conference presentations
Professional referrals
Patient advocacy relationships
Strategic partner introductions
Sustainable barriers
Why rBIO’s position is defensible
rBIO’s competitive advantage comes from process know-how, time advantage, and platform expansion.
Barriers
3-year head start
Proprietary process and know-how
Insulin-first focus
Licensing model
Expansion across multiple peptides
Existing partner and licensee conversations
Financials
Capital supports a defined path to licensing revenue
rBIO’s financing strategy moves the company from process scale-up to commercial readiness and licensing revenue.
The current funding plan supports four priorities:
Complete commercial-scale process development
Prepare the process for licensing
Build the licensee pipeline
Expand the platform across additional markets and peptide drugs
Funding path
From commercial scale-up to licensing revenue
The current financing plan combines a $5.5 million seed round with a planned $18 million Series A.
The seed round moves rBIO through commercial-scale development and process readiness. The Series A supports licensee acquisition, broader commercialization and strategic growth.
| Stage | Capital | Primary objective |
|---|---|---|
| Seed round | $5.5M | Complete commercial-scale process development and prepare the platform for licensing. |
| Commercial readiness | Milestone-based | Establish a repeatable manufacturing process for partner transfer. |
| Licensing revenue | Partner-driven | Secure regional licensees and generate licensing revenue. |
| Series A | $18M | Expand the licensee base, enter additional markets and advance strategic growth. |
Use of seed funds
Focused investment in scale-up and commercialization
The $5.5 million seed round allocates capital across three workstreams:
Scale-up: $3.0 million
Business development and licensing: $2.0 million
Operations and team: $0.5 million
The largest allocation advances the manufacturing process to commercial scale. Business-development funding builds the licensee pipeline and supports market entry. Operating capital funds the team and infrastructure required for execution.
| Use of funds | Amount | Allocation | Purpose |
|---|---|---|---|
| Scale-up | $3.0M | 55% | Complete commercial-scale process development and production readiness. |
| Business development and licensing | $2.0M | 36% | Build the licensee pipeline, advance partner discussions and support market entry. |
| Operations and team | $0.5M | 9% | Fund the personnel and operating infrastructure required for execution. |
Customer economics
Licensing creates attractive customer economics
rBIO’s first-customer model projects a lifetime value of $30 million against a customer-acquisition investment of $3.5 million.
This produces an estimated LTV/CAC ratio of 8.6x.
The model reflects the value of a long-term licensing relationship relative to the technical, commercial and relationship-development investment required to secure a licensee.
| Metric | Current model |
|---|---|
| Customer lifetime value | $30M |
| Customer acquisition cost | $3.5M |
| LTV/CAC | 8.6x |
Financial model
Licensing revenue drives operating scale
The current financial model projects:
Revenue beginning in Q5
Operating profit turning positive in Q7
Net cash turning positive in Q15
Increasing revenue and operating profit as licensing activity expands
The model reflects a licensing-first commercialization strategy with limited owned manufacturing infrastructure.
Summary table
| Financial milestone | Current projection |
|---|---|
| Revenue begins | Q5 |
| Operating profit turns positive | Q7 |
| Net cash turns positive | Q15 |
| Minimum projected net cash | Approximately $(5.8)M |
Risk mitigation and strategic value
rBIO’s licensing-first model addresses the core technical, capital and commercialization risks associated with scaling a new biomanufacturing process.
The company advances through defined technical milestones, milestone-based funding and targeted licensing relationships. This approach builds commercial validation while creating strategic value for organizations seeking insulin and peptide-manufacturing capabilities.
Exit strategy
Strategic value for established industry participants
rBIO’s exit strategy centers on organizations seeking peptide-manufacturing capability, more efficient insulin production, expanded U.S. or regional manufacturing infrastructure, and access to a proprietary licensing platform.
The company’s licensing model creates multiple strategic paths, including acquisition, platform partnership and regional commercialization agreements.
| Strategic Category | Industry Need | rBIO Strategic Value |
|---|---|---|
| Biologics CDMOs | Expanded peptide-manufacturing capability | Adds an insulin-focused process and licensing platform. |
| Pharma Services Companies | Broader manufacturing infrastructure and technical services | Adds proprietary insulin-production know-how and process-transfer capability. |
| Strategic Pharma Companies | Improved manufacturing economics and supply flexibility | Supports lower-cost insulin production and regional licensing. |
| Biosimilar Manufacturers | Insulin-production capability and margin improvement | Provides access to a higher-output manufacturing process. |
| Regional Manufacturing Partners | Local production and market access | Creates a country- or region-specific licensing path. |
Risk mitigation
Defined risks. Defined responses.
rBIO addresses the principal risks investors evaluate in an early-stage biomanufacturing company: process scale-up, CMC readiness, capital requirements, and licensee adoption.
| Risk | Current Position | Mitigation |
|---|---|---|
| Process Scale-up | 20L pilot work completed | Advance the process through 1,000L optimization over an approximately nine-month scale-up program. |
| CMC Readiness | Exploratory animal testing completed successfully | Complete the process-development and manufacturing package required for partner transfer and commercialization. |
| Capital | Licensing-first commercialization model | Deploy capital against defined technical and commercial milestones rather than building and owning every manufacturing asset. |
| Licensee Adoption | Targeted regional licensee strategy and licensing interest | Focus on markets and partners with clear insulin demand, manufacturing infrastructure and margin pressure. |
| Commercial Execution | Experienced scientific, financial and governance team | Coordinate technical scale-up, licensing development and investor strategy through an integrated commercialization plan. |
Three things to remember
Investment thesis summary
Manufacturing inefficiency drives drug costs
Insulin remains essential, but manufacturing complexity creates persistent cost, margin and supply pressure.
rBIO’s process doubles output
rBIO’s proprietary process doubles the rate of insulin production compared with current industry production.
Higher output improves manufacturing economics
Increased output lowers production cost, strengthens licensee economics and supports broader access to insulin.
Investor FAQ
Key information about rBIO’s technology, licensing model, market strategy, development stage, and funding plan.
-
BIO has developed a proprietary insulin manufacturing process and licensing platform that doubles production output compared with current industry production.
The company licenses its process and manufacturing know-how to qualified partners, beginning with insulin and expanding to additional peptide drugs over time.
-
Insulin is a large, essential drug category with persistent manufacturing-cost, supply and margin pressures.
It provides rBIO with a defined beachhead market, established demand and a clear path to regional and strategic licensing.
-
rBIO uses a bacteria-based production process and proprietary manufacturing know-how to produce insulin more efficiently than conventional approaches.
The process increases output, simplifies manufacturing economics and supports transfer to qualified licensing partners.
-
rBIO has completed 20L pilot work and exploratory animal testing.
The next major technical milestone is scale-up to 1,000L production, followed by completion of the manufacturing and CMC package required for licensing.
-
rBIO licenses its manufacturing process rather than building and owning every production facility.
Qualified partners provide regional manufacturing infrastructure, market access and commercialization capabilities. rBIO provides the process, operating know-how and technical transfer required to produce insulin.
-
rBIO’s target licensees include:
Biosimilar manufacturers
Traditional pharmaceutical companies
CDMOs and contract manufacturers
Regional drug manufacturers
Distributors
Fill-finish owners
The company prioritizes partners with insulin demand, manufacturing capability, market access and pressure to improve production economics.
-
rBIO generates revenue through licensing agreements with qualified manufacturing and commercialization partners.
The licensing model supports regional expansion while limiting the capital required to build and operate wholly owned manufacturing facilities.
-
rBIO’s competitive position is based on:
A three-year development head start
Proprietary process know-how
Insulin-specific manufacturing experience
A licensing-first commercialization model
Expansion across multiple peptide drugs
Existing relationships with prospective partners and licensees
-
The next milestones include:
Complete 1,000L process scale-up
Finalize the license-ready manufacturing package
Expand the licensee pipeline
Execute regional licensing agreements
Begin licensing revenue
Extend the platform to additional peptide drugs
-
rBIO’s current financing plan includes a $5.5 million seed round to fund process scale-up, business development, licensing and operating execution.
A planned $18 million Series A supports broader commercialization, licensee expansion and strategic growth.
-
The current plan allocates the $5.5 million seed round across three workstreams:
$3.0 million for scale-up
$2.0 million for business development and licensing
$0.5 million for operations and team
-
The principal risks are process scale-up, CMC readiness, capital requirements and licensee adoption.
rBIO addresses these risks through completed pilot work, milestone-based use of capital, a licensing-first model, targeted regional partners and an experienced scientific, financial and governance team.
-
Prospective investors can use the investor inquiry form to request the investor deck, financial information or a conversation with rBIO management.